The ability of prenatal cell-free DNA sequencing to incidentally detect occult maternal malignancies was first documented over a decade ago, yet coordinated follow-up of pregnant people who receive these results is still lacking in many countries. Here we provide a call to action for oncologists to become more involved in diagnosing and managing these cases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bianchi, D. W. et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 314, 162–169 (2015).
Dharajiya, N. G. et al. Incidental detection of maternal neoplasia in noninvasive prenatal testing. Clin. Chem. 64, 329–335 (2018).
Ji, X. et al. Identifying occult maternal malignancies from 1.93 million pregnant women undergoing noninvasive prenatal screening tests. Genet. Med. 21, 2293–2302 (2019).
Lenaerts, L. et al. Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. eClinicalMedicine 35, 100856 (2021).
Goldring, G. et al. Maternal malignancy after atypical findings on single-nucleotide polymorphism-based prenatal cell-free DNA screening. Obstet. Gynecol. 141, 791–800 (2023).
Heesterbeek, C. J. et al. Noninvasive prenatal test results indicative of maternal malignancies: a nationwide genetic and clinical follow-up study. J. Clin. Oncol. 40, 2426–2435 (2022).
Heesterbeek, C. J. et al. Comprehensive recommendations for the clinical management of pregnant women with noninvasive prenatal test results suspicious of a maternal malignancy. JCO Oncol. Pract. https://doi.org/10.1200/op.23.00594 (2024).
Rink, B. D., Stevens, B. K. & Norton, M. E. Incidental detection of maternal malignancy by fetal cell-free DNA screening. Obstet. Gynecol. 140, 121–131 (2022).
Norton, M. E. et al. Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results. Am. J. Obstet. Gynecol. 229, 300.e301–300.e309 (2023).
Dow, E. et al. Cancer diagnoses following abnormal noninvasive prenatal testing: a case series, literature review, and proposed management model. JCO Precis. Oncol. 5, 1001–1012 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Turriff, A.E., Bianchi, D.W. Oncologists must act to manage cancer detected through prenatal screening. Nat Rev Cancer (2024). https://doi.org/10.1038/s41568-024-00719-1
Published:
DOI: https://doi.org/10.1038/s41568-024-00719-1
